recurrent squamous cell lung carcinoma
Showing 1 - 10 of 10
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 Trial in Canada, United States
Active, not recruiting
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Ipilimumab
- +4 more
-
Birmingham, Alabama
- +1206 more
May 6, 2022
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 Trial in United States (drug, biological,
Completed
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Docetaxel
- +2 more
-
Birmingham, Alabama
- +992 more
Dec 1, 2021
Treating Recurrent Stage IV Squamous Cell Lung Cancer
Active, not recruiting
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Docetaxel
- +12 more
-
Birmingham, Alabama
- +1003 more
Nov 29, 2021
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7 Trial in Houston (ABBV-399)
Completed
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC V7
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021
ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation Trial in Canada, United States (Laboratory Biomarker Analysis,
Completed
- ATM Gene Mutation
- +20 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +1156 more
Jun 22, 2021
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification Trial in United States (Docetaxel, Laboratory
Completed
- CCND1 Gene Amplification
- +5 more
- Docetaxel
- +2 more
-
Birmingham, Alabama
- +1064 more
May 25, 2021
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification Trial in Canada, United States (Docetaxel, FGFR
Completed
- FGFR1 Gene Amplification
- +7 more
- Docetaxel
- +2 more
-
Birmingham, Alabama
- +1083 more
May 25, 2021
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma Trial in Canada, United States (Laboratory
Completed
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma
- Laboratory Biomarker Analysis
- Taselisib
-
Birmingham, Alabama
- +1110 more
Sep 29, 2020
MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 Trial in United States
Terminated
- MET Positive
- +2 more
- Erlotinib Hydrochloride
- +2 more
-
Jonesboro, Arkansas
- +626 more
Mar 17, 2020
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma Trial (Docetaxel, Laboratory Biomarker Analysis,
Withdrawn
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma
- Docetaxel
- +3 more
- (no location specified)
Oct 28, 2015